CATL Shares Jump as $5.6 Billion Buyback Signals Confidence in Long-Term Growth 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
CXMT IPO Debut in Shanghai Puts $85.5 Billion Chipmaker in Spotlight 
ASML, Applied Materials Slide as China DUV Chip Equipment Breakthrough Sparks Market Jitters 
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue 
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance 
Seagate Stock Jumps as AI-Fueled Earnings Beat and Strong FY2027 Outlook Impress Investors 
Zabka Shares Drop 10% as Seven & i Abandons Investment Plans 
Galp Shares Fall After Q2 EBITDA Miss Despite Profit Beat and Higher Dividend 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
Brown-Forman Rejects Sazerac’s $15 Billion Takeover Bid as Family Backs Independence 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Nvidia Eyes $250B Guarantee for OpenAI’s Massive Ohio AI Data Center Project 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Pfizer Inc.'s application for emergency use authorization in the US for its potential coronavirus vaccine will be not earlier than the third week of November.
The US pharmaceutical giant is one of several companies during final-stage clinical trials for potential coronavirus vaccines in the country.
According to Chairman and CEO Albert Bourla, Pfizer may find out later this month whether or not its vaccine can help prevent COVID-19 in at least a majority of those vaccinated.
if data from trials support the move, Pfizer will apply for emergency use authorization in the US after the safety milestone is achieved in the third week of November.
The US Food and Drug Administration requires companies to provide two months of safety data on half of the trial participants following the final dose of the vaccine.
Pfizer, which is developing the vaccine with Germany's BioNTech SE, has agreed to supply Japan with 120 million doses of a vaccine for 60 million people if the development efforts are successful.
Another American pharmaceutical firm Moderna Inc. revealed it wouldn't be ready to seek emergency use authorization before Nov. 25.
US President Donald Trump has been raising expectations that vaccines could be ready before the Nov. 3 presidential election.
